Cationic Poloxamer Additives for Low-Toxicity Viral Transduction
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current viral transduction methods face inefficiencies due to low virus diffusion rates, rapid inactivation, and toxicity issues with existing chemical adjuvants like polybrene, particularly when targeting sensitive cells, necessitating high virus concentrations and costly production scales.
Innovation Solution
Introduce cationic poloxamers with both hydrophilic and hydrophobic regions and cationic functions at the polymer backbone to enhance viral transduction, optionally combined with magnetic nanoparticles, providing synergistic effects without additional cationic polymers.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If high virus concentrations are used to improve transduction efficiency, then transduction efficiency is improved, but production costs increase
Solution Approach 1:
The patent introduces polybrene as a chemical intermediary substance that mediates between the virus and target cells. Polybrene enhances viral transduction by facilitating virus-cell interaction, allowing effective transduction at lower virus concentrations, thereby reducing production costs while maintaining high transduction efficiency
Solution Approach 2:
The patent changes the chemical parameters of the transduction system by adding polybrene, which alters the physical-chemical environment of the virus-cell interaction. This parameter change enables efficient transduction with reduced virus dosage, directly addressing the contradiction between transduction efficiency and production cost
2Reliability
If polybrene is used to enhance transduction, then transduction efficiency is improved, but cell toxicity increases
Solution Approach 1:
The patent optimizes the concentration parameters of polybrene to achieve the minimum effective dose that enhances transduction while remaining below toxic thresholds. By precisely controlling the polybrene concentration parameter, the system achieves high transduction efficiency while minimizing cell toxicity
Solution Approach 2:
The patent applies partial action by using sub-maximal concentrations of polybrene that are sufficient to enhance transduction but do not reach levels that cause significant cellular toxicity. This partial application of the chemical adjuvant resolves the contradiction between efficacy and safety
3Reliability
If virus production is upscaled to meet clinical demand, then transduction efficiency is improved, but production complexity increases
Solution Approach 1:
By introducing polybrene as a chemical mediator, the patent reduces the required virus concentration by a factor of 5-10 times. This intermediary substance simplifies the production process by eliminating the need for complex large-scale virus production and concentration systems, thereby reducing production complexity while maintaining clinical efficacy
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Enhances viral transduction efficiency across various cell types, reducing the need for high virus concentrations and minimizing toxicity, thus lowering production costs and risks.
Implementation Method 1
The structure of this additive incorporates both hydrophilic and hydrophobic regions which represents different areas in the backbone of the polymer. This polymeric construction is ended by cationic chemical functions which contribute to further enhance the viral transduction.
Implementation Method 2
Another embodiment of the present invention relates to the colloidal stabilization of iron-based nanoparticles using these polymers and their use in increasing transduction efficiency.
Data Source
AI summary
Disclosed is a method for the enhancement of the transduction of a target cells by a viral vector using a cationic block-copolymer introduced as an additive alone or formulated with nanoparticles. The method includes a step of contacting a target cells with viruses and a cationic block co-polymer. The structure of this additive incorporates both hydrophilic and hydrophobic regions which represents different areas in the backbone of the polymer. This polymeric construction is ended by cationic chemical functions which contribute to further enhance the viral transduction. Also disclosed are new cationic poloxamers that can be used in the disclosed method. Furthermore, another embodiment is the colloidal stabilization of iron-based nanoparticles using these polymers and their use in increasing transduction efficiency.